The structural diversity of natural products provides a major source for discovering antimicrobials with novel structures or mechanisms to overcome microbial resistance. Herein, we prepared a series of rutaecarpine-pyridinium quaternary ammonium conjugates by using rutaecarpine as the lead compound. Bioactivity evaluation demonstrated that 5dl exhibits outstanding antibacterial activity against S. aureus ATCC 29213 and clinical MRSA isolates, with MIC values ranging from 0.5 to 2 μg/mL, comparable to vancomycin. Low hemolysis, low resistance frequency, low cytotoxicity, rapid bactericidal properties, and good plasma stability indicate the further application potential of 5dl. Notably, 5dl exhibited better therapeutic efficacy than vancomycin in two mouse models of MRSA infection. Mechanistic studies revealed that 5dl not only targetingly disrupts the MRSA cell membranes but also inhibits Topo I activity, thereby interfering with DNA replication and transcription processes, ultimately leading to MRSA cell death. These findings demonstrate that 5dl could serve as a promising candidate for combating MRSA infections.
Xu et al. (Mon,) studied this question.